Professor of Neurology and Neurobiology
- Senior Wellcome Clinical Scientist
- Honorary Consultant Neurologist
My research aim is to gain a better understanding of the response of the nervous system to injury in order to develop strategies to promote peripheral nerve repair and to prevent the development of neuropathic pain. This is complementary to my clinical interest in peripheral neuropathy and as such links with my specialist neuropathy clinical service at the Oxford University Hospitals. I employ a variety of techniques including cell culture, preclinical transgenic models and transcriptional profiling as well as biomarker, psychophysical and genetic studies in neuropathy patients. This research programme is leading to a better understanding of the signaling events required for effective nerve repair and improved means of patient stratification. I have been involved in understanding the genetic basis of inherited painful channelopathies (for instance familial episodic pain syndrome due to TRPA1 mutations) and in the description and validation of novel pain mediators such as NGF and CXCL5. In the case of NGF a monoclonal antibody aimed at this factor has shown efficacy in phase 3 clinical trials. I am a member of the London Pain Consortium, a PI on the Innovative Medicines Initiatives ‘Stembancc’ and I am vice director of the ‘Europain’ IMI project.
Defining the Functional Role of NaV1.7 in Human Nociception.
McDermott LA. et al, (2019), Neuron, 101, 905 - 919.e8
DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain
Pascal MMV. et al, (2019), Wellcome Open Research
Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury
Baskozos G. et al, (2019), PAIN, 160, 463 - 485
Feasibility of Diffusion Tensor and Morphologic Imaging of Peripheral Nerves at Ultra-High Field Strength
Schmid AB. et al, (2018), Investigative Radiology, 53, 705 - 713
The Novel Activity of Carbamazepine as an Activation Modulator Extends from NaV1.7 Mutations to the NaV1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy.
Han C. et al, (2018), Mol Pharmacol, 94, 1256 - 1269